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Abstract  
Introduction: The manufacturer of pregabalin has a second use patent covering prescribing for 
neuropathic pain: its principal indication. The manufacturer has threatened legal action in the UK if 
generic pregabalin rather than Lyrica is prescribed for this indication. No problems exist for 
practitioners who prescribe pregabalin for epilepsy or generalized anxiety disorder. This has serious 
implications for health authorities. In Germany, however, generics could be legally prescribed for any 
approved indication once one indication loses its patent.  
 
Aim: To establish the current situation with pregabalin among principally European countries. 
 
Methods: Personnel from 33 regional and national health authorities mainly from Europe, and nine 
from universities across Europe working as advisers to health authorities or with insight into their 
activities, were surveyed regarding four specific questions via email to shed light on the current 
situation with Lyrica and pregabalin in their country. The information collated from each country was 
subsequently checked for accuracy with each co-author by email and face-to-face contact and 
collated into five tables. 
 
Results: The scenarios ranged from extending the patent life of Lyrica (e.g. France), endorsing the 
prescribing of Lyrica for neuropathic pain (e.g. Catalonia and South Korea), and current prescribing of 
pregabablin for all indications (e.g. Serbia and Germany). Little activity has taken place in European 
countries in which generic pregabalin is not yet reimbursed.  
 
Conclusion: The availability of generic pregabalin has prompted a number of different activities to be 
undertaken among the 33 countries and regions surveyed. The situation in Serbia and the historic 
situation in Germany provide examples of ways to maximize savings once a product loses its patent 
for at least one indication. 
 
Keywords: Health authorities, generics, Lyrica, pregabalin 
 
Introduction 
 
The increased use of generic medicines is essential to sustain healthcare systems given the ever 
increasing pressure on resources (1-4). Prices of generic drugs are as low as 2±10% of pre-patent 
loss prices in some countries (5-7). Consequently, increased use of generic drugs can generate 
substantial savings, which can be re-directed into funding new valued high-priced medicines (2, 5-12), 
which is especially important for countries struggling to fund these medicines. A number of strategies 
globally have been initiated to encourage prescribing and dispensing of generic drugs rather than the 
originator (brand-name) drug, as well as patented products in a class in which all medicines are seen 
as essentially similar at therapeutically equivalent doses (4, 8-12).  
 
Increasing use of generic drugs does not appear to compromise care, and many studies have 
reported little or no difference in outcomes between the two across a range of products and classes 
(13-18),Q(XURSHRQO\JHQHULFGUXJVSURGXFHGLQDFFRUGDQFHZLWKWKH(XURSHDQ0HGLFLQH¶V
$JHQF\¶VVWULFWJXLGHOLQHVDQGdefinitions (19) are granted marketing authorization.  
  
Well-known and agreed exceptions to generic prescribing or substitution include lithium, 
theophyllines, some anti-epileptic drugs, modified release preparations and immunosuppressants.  In 
these cases, brand-name prescribing is endorsed (20-23). Agreed exceptions to generic prescribing 
including medicines to treat epilepsy and prevent organ rejection also exist in Germany and Sweden 
(6, 24). 
 
A new emerging problem, however, has come to the fore in recent years, concerning the expiry of 
patents for generic drugs that have patents for more than one indication, and the threat of legal action 
by the manufacturer of the originator drug against physicians. This situation occurred recently in the 
case of pregablin for the treatment of generalized anxiety disorder (GAD) when the basic patent for 
pregabalin expired in July 2014 in a number of European countries. The patent for its second medical 
usHSURWHFWLQJWKHRULJLQDWRUGUXJ/\ULFD¶Vuse in treating pain, extends to July 2017 in Europe (25, 
26). In the UK, this resulted in the manufacturer of the originator drug (Lyrica) claiming patent 
infringement and warning doctors not to prescribe the generic drug pregablin for neuropathic pain (26, 
27). As far as we are aware, this is the first time this has happened, and has serious implications for 
health authorities.  
 
Prior to this, the originator manufacturer of Lyrica  had been fined heavily for promoting gabapentin 
(prelude to pregabalin) off label for the treatment of neuropathic pain (28-31), although it is now 
registered for this indication (43). In addition, there have been concerns with the methodological 
limitation of  some of the studies of pregabalin in neuropathic pain(32-34). Pregabalin, for example, is 
currently not OLVWHGLQWKHµ:LVH/LVWRI6WRFNKROP0HWURSROLWDQ+HDOWKFDUH5HJLRQbecause of efficacy 
and safety concerns compared with other treatments for these conditions (35). However, there are 
increasing concerns with the implications of the activities of second use patents with Lyrica (26, 36). 
 
In this paper, historical developments in the UK and Germany relating to this case are examined. 
Personnel from regional and national health authorities from principally across  Europe, and advisors 
to health authorities working in universities, were then surveyed to ascertain the current situation with 
pregabalin in their country and to determine the best strategy for maximizing savings for countries 
once a product loses its patent for any indication. 
 
United Kingdom 
 
In the UK, International Nonproprietary Name (INN) prescribing rate is over 80% and up to  98±99% 
of non-contentious generic drugs such as proton pump inhibitors, renin-angiotensin inhibitors and 
statins, with pharmacists not permitted to substitute an originator drug with a generic drug when the 
originator drugs is prescribed (7, 20, 21, 37).  
 
The UK Medicines Agency recently issued advice on which epilepsy drugs to prescribe by brand 
name (originator) and which by INN (38). Pregabalin was considered suitable for INN prescribing (38), 
which was endorsed by the originator company stating µthere will be no clinical superiority of the 
originator branded medicine Lyrica® over generic pregabalin¶(25).  
 
The extended patent for neuropathic pain resulted in the originator company writing to all Clinical 
Commissioning Groups (CCGs) in November 2014 pointing out that generics of pregabalin were 
expected to be approved only for GAD and epilepsy indications only, and that the prescribing of 
generic pregabalLQIRUQHXURSDWKLFSDLQZRXOGUHSUHVHQWµRII-ODEHO¶XVH. This would  be considered a 
patent infringement constituting an unlawful act, with the originator company reserving all legal rights 
in this regard (25-27).  
 
The wish of generic companies to make generic pregabalin available in the UK across all indications 
resulted in a court case, with the originator company as claimant and the Actavis group as the 
principal defendant (26, 39). The Judge in his deliberations, posted on 21 January 2015, granted 
Actavis the possibility to launch generic pregabalin and again stated that the best way forward was to 
try to ensure physicians prescribe Lyrica for the treatment of neuropathic pain and pregabalin for 
other conditions, including epilepsy (39, 40).  
 
The actions of the originator company are unsurprising. In 2013, global sales of Lyrica generated $4.6 
billion for the company (39). In the UK, sales of Lyrica increased by 53% between 2011 and 2013 to 
about US$310 million. It is estimated that 54% of prescriptions in September 2014 were for treating 
pain, of which 44% was for neuropathic pain (39). In 2014, sales of Lyrica were GB£250million 
(US$390million) (26).The potential loss in revenue therefore, would hugely impact company sales - 
estimated to be £GB 220million per year (US$340million) across all indications assuming high INN 
prescribing rates and generic prices rapidly falling by 90% of the price of Lyrica (7, 41) . 
 
In an attempt to preserve sales of Lyrica, the originator company has been proactive in lobbying 
groups in the UK who could influence physician prescribing, such as the Medicine Management 
groups within CCGs, The Pharmaceutical Services Negotiating Committee, The General Practice 
Committee of the BMA, and the National Health Service (26, 36, 42-44). For instance, NHS England 
in March 2015 issued advice to all CCGs that within electronic prescription systems there should be a 
notice or advice box stating µIf treating neuropathic pain, prescribe Lyrica (brand) due to patent 
SURWHFWLRQ)RUDOORWKHULQGLFDWLRQVSUHVFULEHJHQHULFDOO\¶ (43). The Pharmaceutical Services 
Negotiating Committee stated to its members they should be aware that the originator company still 
retains the indication for neuropathic pain. Members were also made aware that following a high court 
GHFLVLRQµit was agreed by all parties that the generic producers would write to CCGs to ensure they 
were aware that the generic could not be supplied for the patented indication.  A CCG or other party 
WKDWSURPRWHVWKHVXSSO\RIJHQHULFSUHJDEDOLQIRUWKHSDWHQWHGLQGLFDWLRQULVNVIDFLQJOHJDODFWLRQ¶ 
(42). 
 
This situation in the UK has important future implications for generic and biosimilar companies across 
countries, as it may impede the ability of health authorities to fully realize potential savings from 
generics and biosimilars once the first indication loses its patent, especially if pharmaceutical 
companies look to extend the number of indications for their new medicines once launched in an 
attempt to extend the patent life. 
 
Germany 
 
Germany has taken a different approach to the UK. Currently, nine pregabalin generics are available 
and reimbursed in Germany (up to April 2015), all of which have the indications for epilepsy and 
anxiety disorders. The situation, however, is now less clear cut as the originator manufacturer, has 
taken Ratiopharm, Hexal, 1A Pharma, Glenmark, and Aliud Pharma and some Sickness Funds to 
court in an attempt to conserve Lyrica sales for neuropathic pain (10 April 2015) (45). The legal battle 
is VWLOORQJRLQJ7KHRULJLQDWRUFRPSDQ\¶VSUHYLRXVVWUDWHJ\WRSURPRWH/\ULFDZDVWRFRPPXQLFDWH
GLUHFWO\ZLWKSK\VLFLDQVRUYLD.9¶V(regional doctors´ associations) by letter, making it clear that Lyrica 
was the only pregabalin licensed for neuropathic pain. However, these communications were largely 
GLVPLVVHGE\.9¶VEHFDXVHWKHIRFXVZDVRQOHJDOUDWKHUWKDQPHGLFDOLVVXHVDQGWKH.9¶V
continued to advise physicians to reach targets of generic prescribing of at least 85%. In addition, the 
Social Code Book V (SGB V), which is decisive for Sickness Funds (German payers), stated in 
paragraph 129 that generic substitution is possible wherever at least one indication matches (46-49). 
 
The contrast between the situation the UK and the situation in Germany, and the implications for  
potential savings when other pharmaceutical products lose their patents for some but not all 
indications, has led health authorities, principally across Europe, to review the current status of 
pregabalin in other countries in order to refine their own strategies if possible. 
 
Aim of study 
 
A qualitative study was undertaken to ascertain the current situation between generic pregabalin and 
Lyrica among health authorities from principally across Europe. This included a range of Central, 
Eastern and Western European countries with different epidemiology and funding of health care, as 
well as policies to enhance the prescribing of generics. This builds on the situation in England and 
Germany, and is in line with current recommendations for conducting cross-national research projects 
(50). The aim was to maximixe future savings for countries once a product loses its patent for any 
indication. 
 
Materials and methods  
 
Personnel from 33 regional and national health authorities mainly from across Europe, and personnel 
from nine universities working closely as advisers to health authorities or with insight into health 
authority activities, were contacted by email to provide answers to the following four questions (up to 
April 2015):  
 
(1) Are you aware of any similar examples to the situation of pregabalin and Lyrica in the UK from 
other pharmaceutical companies for small molecules once the patent has been lost (biosimilars are a 
different issue)? If so, what were these and how were they handled (if at all);  
(2) Was Lyrica reimbursed in your country? If yes, for what indications?  
(3) Has generic pregablin been launched in your country/ about to be launched? If yes what date 
(month) and indications?  
(4) has the originator company issued a letter to healthcare professionals in your country similar to the 
letter issued to CCGs in the UK? If yes, what actions (if any) are being taken? 
 
This was supplemented with knowledge from other high-income countries taking different approaches 
to the availability of generic pregabalin to potentially provide additional examples. 
 
All health-authority personnel are involved with either pricing and reimbursement decisions, decisions 
concerning funding or use of medicines, or both, including generics, in their countries and regions. 
Consequently, it was felt that they would have the most insight into the current situation concerning 
pregabalin and Lyrica in their countries and regions. European countries included those from 
Western, Central and Eastern Europe to ensure legitimacy with the findings. Personnel from regions 
in the Netherlands, Sweden and UK were also included, as healthcare budgets in these regions are 
devolved downwards.  
 
The written information supplied by the co-authors and others for each of the questions for each 
country was collated and summarized by one author (BBG). The summarized information was 
subsequently checked via email and face-to-face contact with the relevant co-author(s) to ensure the 
accuracy of the summarized information. The information supplied was subsequently summarized into 
five categories to improve the interpretation of the findings and the implications for the future, building 
on the situation in England and Germany.  
 
The five categories included: 
x Countries in which Lyrica was never reimbursed; consequently generic pregabalin is less of an 
issue for the originator company (Table 1). 
x Countries in which the patent life for Lyrica has been extended, negating the threat from generic 
pregabalin until all three indications have lost their patent (Appendix 1).  
x Countries in which generic pregabalin is currently not reimbursed and the future situation is 
currently unknown (Appendix 2). 
x Countries in which generic pregabalin is currently not reimbursed; however, the country is likely to 
follow the example of either UK and restrict the prescribing of pregabalin for neuropathic pain, 
alternatively reimburse pregabalin across all indications (Table 2) . 
x Countries in which pregabalin is available and reimbursed (Table 3).  
 
Potential or actual demand-side measures among the health authorities were not broken down into 
WKHµIRXU(V¶HGXFDWLRn, engineering, economics and enforcement, as in our previous paper on 
generic clopidogrel (51). This is because pregabalin may not be available and reimbursed across 
Europe and the other chosen countries.  
 
This information was supplemented with a limited literature search for further information about 
generics generally, pregabalin and the activities of the originator company, including recent court 
cases, as well as relevant papers known to the co-authors. A similar methodological approach was 
used when reviewing health authority activities when generic clopidogrel became available (51).  
 
Results 
 
The results of the survey revealed that respondents were typically unaware of similar examples to 
pregabalin and Lyrica in their countries. For example, generic clopidogrel was reimbursed and 
endorsed by health authority personnel from across Europe despite generic clopidogrel not including 
all licensed indications at launch (51). The main exception was Lithuania (Table 2) with Glivec and 
generic imatinibum. 
 
The current situation for Lyrica and generic pregabalin among health authorities and health insurance 
companies across Europe and other selected countries is included in Tables 1±3 as well as Appendix 
A1 and A2. This also includes additional activities in Scotland. 
 
Table 1 ± Countries in which LYRICA was never reimbursed.  
 
Country Health authority situation 
Latvia  x In Latvia, generics of a certain INN are reimbursed for the same indications as the 
originators, irrespective of the number of indications for the generic versus the 
originator. A recent example is generic imatinibum, which has been reimbursed for 
all indications since 2013. 
x No patent protection issues are evaluated by the national health service in Latvia 
when making reimbursement decisions when a generic manufacturer has 
received marketing authorization and is applying for reimbursement. 
x A reference pricing system is in place, and the reference price (which is paid by 
the state) is the price of the cheapest product. 
x Lyrica is listed but currently not reimbursed in Latvia (100% co-pay), including 
neuropathic pain. 
x Pregabalin Pfizer is centrally registered. Currently, however, no generic 
pregabalins are available and reimbursed in Latvia. 
x Once available and reimbursed, it is likely that generic pregabalin will be available 
across all indications similar to the current situation with imatinibum. 
New 
Zealand 
x Pregabalin (originator or generic) is currently not funded on the New Zealand 
Pharmaceutical Schedule in either hospitals or the community for any indications. 
Lyrica, however, is currently registered for use in New Zealand with indications for 
neuropathic pain in adults and epilepsy with partial seizures, with or without 
secondary generalization. 
x Instead, gabapentin is funded on the New Zealand Pharmaceutical Schedule for 
epilepsy and for neuropathic pain or chronic kidney disease-associated pruritus, 
with Special Authority restrictions and requirements. 
x PHARMAC (NHZ=HDODQG¶Vpharmaceutical funding agency) received an 
application for pregabalin (Lyrica, Pfizer) for neuropathic pain in 2011 (52). The 
advice from the Pharmacology and Therapeutics Committee (PTAC, the clinical 
advisory body to PHARMAC) and both its Analgesic and Neurological 
subcommittees has been that, despite unmet need in the management of 
neuropathic pain and a clear need for effective treatments, pregabalin has similar 
effects to gabapentin (albeit faster onset of action), and is unlikely to offer health 
benefits when gabapentin has failed 
x The advisory committees to PHARMAC subsequently recommended that 
pregabalin only be listed for neuropathic pain if it is cost-neutral with respect to 
gabapentin and subject to the same restrictions;  further details are included in the  
relevant PTAC and subcommittee minutes (53-55).  
x PHARMAC has very recently received an application for pregabalin for 
generalized anxiety disorder. As pregabalin is currently not registered in New 
Zealand for this indication, PHARMAC will not be progressing this application at 
this point. 
x Pegabalin may be funded in the future in New Zealand if a reasonable price is 
tendered with pregabalin being included in the 2013±2014 tender. PHARMAC will 
assess commercial proposals as they arise based on their successful tendering of 
pharmaceuticals (56).  
  
Table 2:  Countries in which generic pregabalin is currently not reimbursed and the future 
situation can be predicted (likely to follow the example of the UK
a
 or likely to reimburse 
pregabalin across all indications given current regulations
b
). 
 
Country Health authority situation 
Lithuaniaa x Lyrica is currently reimbursed (about 60% of use is for neuropathic pain and about 
40% for epilepsy).  
x The authorities in Lithuania received a letter from the originator company similar to 
the letter received by Clinical Commissioning Groups in England. As yet, no 
applications from generic manufacturers have been submitted to market generic 
pregabalin in Lithuania. 
x It is anticipated that, once available, the different products (pregabalin and Lyrica) 
will be dispensed for different indications (similar to the current situation with 
Glivec and generic imatinibum), potentially enforced through pharmacies. 
Netherlandsa  
(57) 
x Lyrica is currently reimbursed and prescribed in the Netherlands for GAD, 
epilepsy and neuropathic pain. 
x There is currently no generic pregabalin, although pregabalin Krka is registered. 
x The originator company issued letters to the Health Insurance Companies in the 
Netherlands including Achmea, which were similar in nature to those issued in the 
UK, with subsequent follow-up visits from senior procurement officers.  
x Once generics are available and reimbursed, the current preference procurement 
model for molecules once multiple sources are available will be hindered by the 
fact that the 2015 preference policy for procurement is closed, only two indications 
for pregabalin can be procured (epilepsy and GAD) and the perceived financial 
impact of generic pregabalin is seen as relatively low. 
x Consequently when two or more generics become available and are reimbursed, 
generic pregabalin may be a candidate for the IDEA procurement model, as 
pharmacists should be able to distinguish between the different indications and 
substitution is not allowed for unapproved indications.  
x Under the IDEA model, there is one fixed price for any µbox of pills¶ with 
procurement undertaken by pharmacists to see if they any savings can be 
obtained. 
Norwaya x Lyrica is currently reimbursed in Norway for use in epilepsy and palliative care in 
the terminal stages. Parallel distributed Lyrica is marketed and substitutable. 
x The indication µneuropathic pain¶LVSDWHQWSURWHFWHGXQWLO-XO\ 
x INN prescribing is possible, but currently limited for these indications.  
x Generic pregabalin with the epilepsy and GAD indications µDUHDXWKRUL]HGEXW not 
\HWODXQFKHG¶ 
x Generic pregabalin and Lyrica are currently being assessed by the medical 
authorities regarding potential substitutability. However, any substitution will not 
include patent protected indications (i.e. neuropathic pain). 
Swedena 
(58, 59)a 
x So far only parallel distributed Lyrica and Pfizer´s own generic preparation are on 
the list of exchangeable generic drugs. 
x The Swedish reimbursement system is in most cases not linked to a specific 
indication, and this was also the case with Lyrica when it was introduced in 2005. 
x Since Lyrica is registered for epilepsy, generic substitution most probably will be 
discouraged via the Swedish Medicines Product Agency (as with all products for 
epilepsy in Sweden), with a revised list of substitutable pharmaceuticals imminent. 
In addition, the 6ZHGLVKV\VWHPGRHVQ¶WDOORZLQIRUPDWLRQDERXWWKHSUHVFULELQJ
indication to be communicated to the pharmacy and used in decisions about 
reimbursement 
x In 2014, Lyrica was again re-evaluated by the TLV (Swedish Reimbursement 
Agency) owing to concerns with compliance. As a result, the originator company 
agreed to lower its price in exFKDQJHIRU7/9PDNLQJQRFKDQJHVWR/<5,&$¶V
reimbursement status. 
x The originator company has written to the County CouncilV¶ (Region) Drug and 
Therapeutic Committees (DTCs) requesting meetings to discuss the situation 
regarding LYRICA and generic pregabalin (January and February 2015). This is 
being monitored especially with pregabalin (Lyrica) typically not recommended in 
regional formularies. 
Austriab x At least three pregabalin generics have received marketing authorization in 
Austria: one is the branded generic from Pfizer (pregabalin Pfizer, authorized on 
10 April 2014, centralized procedure, with all three indications, including 
neuropathic pain). The other two are Pregabalin Krka, authorized on 7 January 
2015, and Pregabalin ratiopharm on 30 March 2015, both for epilepsy and GAD, 
with the neuropathic pain indication potentially due in the future. More generic 
pregabalin formulations are anticipated 
x So far, HVB (reimbursement agency) has received a reimbursement application 
solely for Pregabalin Krka although others are anticipated. 
x Currently the originator company has not undertaken similar activities to the UK. 
However, the situation is being monitored. According to the Austrian directive for 
economic prescribing, physicians are obliged to prescribe the most economical 
alternative if they are both therapeutically suitable for treatment. As this will be the 
case with pregabalin generics, prescribing generics for neuropathic pain is 
envisaged. 
Polandb x Lyrica is reimbursed but only for neuropathic pain in adults caused by cancer, its 
treatment, or both.  
x The situation is different for gabapentin, which is reimbursed for epilepsy as well 
as pain for patients with cancer (off label). 
x A reference price system currently exists in Poland, including all generics 
(branded, accompanied or not by the name of the manufacturer) as well as the 
originator (brand name). Patients pay a flat rate fee as well as a co-payment of 
0%, 30%, or 50% depending on the indication. There is also a limit of financing 
(calculated using defined daily doses - DDDs) based on the cheapest products, 
with patients paying an additional co-payment if they are prescribed a product 
whose DDD is more expensive than the limit and do not wish it to be substituted. 
Alternatively, the physician has banned substitution. 
x Pharmacists are allowed to substitute in Poland, even if only one indication is 
approved (recent developments by the Ministry of Health), unless physicians write 
µ'Rnot sXEVWLWXWH¶RQWKHSUHVFULSWLRQ, and this can be clinically justified (must be 
GRFXPHQWHGLQWKHSDWLHQW¶VQRWHV. 
x Currently, no generic pregabalin formulations (included branded generics) are 
reimbursed in Poland. This could change, and potentially with an increase in the 
indications including epilepsy and other forms of neuropathic pain, depending on 
prices offered to the Ministry of Health when it updates the national 
reimbursement list. 
x The situation will be closely monitored, especially given the reference price 
system, pharmacists allowed to substitute, patient pressure to lower costs and the 
limited reimbursed indications for Lyrica potentially resulting in limited activities by 
the originator company.     
GAD, Generalized anxiety disorder. 
 
Table 3: Countries in which pregabalin is currently available or reimbursed across all or some 
indications.  
 
Country Health authority situation 
Czech 
Republic 
x Both Lyrica (the originator) and Pregabalin Pfizer (registered with a generic 
reference to the original registration, the marketing authorization holder is the 
same) are currently available. 
x Out of these two, only one (Lyrica) is currently reimbursed (epilepsy, GAD and 
neuropathic pain); however, this is now subject to an ongoing reassessment of its 
reimbursement price. 
x Currently awaiting developments with Lyrica and generic pregabalin in the Czech 
Republic. 
Estonia x Pregabalin is 50% reimbursed in Estonia for epilepsy, GAD and neuropathic pain 
x Currently only Pfizer products are reimbursed (generic pregabalin and LYRICA). 
x In general in Estonia, reimbursement groups are compiled based on INN name, 
and doctors are obliged to prescribe by INN unless originator name is medically 
relevant. 
Finland Lyrica is reimbursed for epilepsy, GAD and neuropathic pain. All indications are 
reimbursed (35%). There is 100% reimbursement (special reimbursement 
category) for patients with epilepsy or other corresponding convulsive states that 
have partial epileptic seizures, or other forms of refractory epilepsy, where Lyrica 
could potentially be beneficial (monitored through pharmacies). 
x The cuUUHQW3KDUPDFHXWLFDOV3ULFLQJ%RDUG¶VGHFLVLRQRQUHLPEXUVHPHQWVWDWXV
for LYRICA is valid through to 31 May 2015 
x Pregabalin KRKA was granted similar reimbursement status for epilepsy and GAD 
on 23 February 2015 with the decision coming into force on 1 April 2015 and valid 
until the end of the year (no information yet when the product will be launched in 
Finland with pregabalin currently not reimbursed for neuropathic pain) 
x Reimbursement for Pregabalin Pfizer has not been applied for. 
x There are pending marketing authorization applications at Fimea (Finnish 
Medicines Agency) for pregabalin products by the following applicants: Actavis 
Group PTC, Orion Pharma, Ratiopharm GmbH and Sigillata Ltd (All applications 
were delivered in July 2014 ± but no further news). 
Republic of 
Srpska, 
Bosnia and 
Herzegovina  
x All medicines reimbursed by Republic of Srpska Health Insurance Fund (RS HIF) 
are by INN. 
x A reference price system currently exists, in which the reimbursed price for the 
molecule is the lowest priced product currently on the market, with patients 
required to cover the difference themselves for a more expensive product. 
x Generic pregabalin is available in Bosnia and Herzegovina for all three 
indications, including the treatment of peripheral and central neuropathic pain in 
adults - Pagamax capsules 25 mg, 75 mg and 150 mg by Nobel Ilaç, Turkey 
(since June 2014) and Epiron capsules 75 mg, 150 mg by Bosnalijek, Bosnia and 
Herzegovina (since February 2015). Pregabalin, however, is currently not 
reimbursed in the Republic of Srpska (100% co-payment). 
x The application for inclusion of Lyrica on the Positive list was discussed by the 
HIF Medicines Committee in November 2012, and then rejected. No new 
application has so far been re-submitted.  
x Consequently, to date, the originator company has not instigated similar activities 
in the Republic of Srpska to those undertaken in the UK. 
Serbia x Lyrica has been on the positive drug list since 2011:  Liste A1 with 85% co-
payment for the indication  of neuropathic pain, and on Liste A for indication 
epilepsy and GAD (lower co-payment).  
x Actavis Zdravlje received marketing authorization from ALIMS from 13 May 2014. 
From  1 January 2015, generic pregabalin was included on the positive drug list 
for all indications as the originator (brand name) product, including neuropathic 
pain. 
x At the moment of entry, the first generic must be priced at least 30% below the 
originator, setting the reimbursement rate for the molecule. 
Slovenia x Lyrica is currently reimbursed by ZZZS (Health Insurance Agency in Slovenia) 
only for epilepsy and neuropathic pain and not for GAD. 
x Generic pregabalin is on the market in Slovenia and currently in the 
reimbursement process 
x However, the potential interchangeability of both formulations (originators and 
generics) has not yet been established by the Agency for Medicinal Products. 
x There are regulations in place in Slovenia, however, to establish a therapeutic 
group (cluster), with the reimbursement level based on the product or molecule 
with the lowest price once at least one indication matches that of the originator. 
South Korea x Currently, 101 generic pregabalin strengths and products are available and 
reimbursed by the National Health Insurance in Korea: 48 for 75 mg, one for 100 
mg, 50 for 150 mg and two for 300 mg. 
x No price difference exists among generics and originators at the same strength. 
x In February 2012, 82 generics were listed across the strengths but generic 
companies were sued for medical use patent infringement by the originator 
company. Following this, the medical use patent for neuropathic pain is protected 
until 14 Aug 2017, with pregabalin generics only available for the treatment of 
epilepsy. 
x Regardless of the patent dispute, the price of Lyrica dropped by 30% in March 
2012 and again by 23.5%. It subsequently kept the same price as the generics in 
February 2013. 
x The originator company filed an administrative appeal for the restitution of the 
drug price in January 2014. The price, however, has not currently changed 
Spain 
(Catalonia) 
x Generic pregabalin has been available since January 2015 for epilepsy and GAD. 
x The originator company issued a letter in Spain (Catalonia) similar to the letter 
issued to CCGs in the UK. As a result, the authorities in Catalonia informed 
physicians that, currently, only Lyrica has the indication for neuropathic pain and 
should be prescribed for this indication (prescriptions can be monitored through 
their electronic prescription system including the diagnosis/indication). 
x In Spain, however, pregabalin is not an economical issue owing to the reference 
price system. The reference price (which is paid by the state) is the price of the 
cheapest product. Consequently to be reimbursed, the originator should reduce its 
price to the generic price. 
x Savings and use of yrica have been enhanced by the originator company 
reducing the price of LYRICA by about 40% from December 2014 to January 
2015. 
UK ± 
Scotland (if 
different to 
England ± 
Box 1) (12, 
60-62) 
x NHS Highland: 
o October 2014: physicians urged to increase the generic use versus 
identified originators including INN prescribing.  
o October and  November 2014: NHS Highland in their newsletter to 
physicians suggested that, although, generic pregabalin will only have two 
indications initially, this should not detract physicians from prescribing 
generic pregabalin. However, the article was subsequently removed from 
WKHQHZVOHWWHUµSHQGLQJGLVFXVVLRQV¶.  
x Activities are ongoing among the other Health Boards in Scotland following a 
similar letter from the originator company to the CCGs in England. 
x Community Pharmacy Scotland, the equivalent of the English PSNC, issued 
advice (February 2015) indicating the need for healthcare professionals to stay 
within licence when the indication is known.  They also suggested that, because 
of the direct to pharmacy distribution model, the originator company will be able to 
identify changes in the use of Lyrica suggesting that generic pregabalin is being 
prescribed outside of the current licence and potentially exposing healthcare 
SURIHVVLRQDOVWRWKHRULJLQDWRUFRPSDQ\¶VSDWHQWSURWHFWLRQVWUDWHJ\ 
GAD, General anxiety disorder; INN, International nonproprietary names. 
 
Discussion 
 
In this paper, we have described the situation across Europe following the launch or imminent launch 
and reimbursement of pregabalin. We were not surprised by the activities of the originator company in 
the UK in view of the current high levels of INN prescribing, no clinical issues with patients being 
switched between generic pregabalin or Lyrica across indications, and the high sales of Lyrica 
globally and in the UK (7, 21, 25, 38, 39, 63). The originator company had also recently experienced 
considerable loss of revenue when both atorvastatin and sildenafil lost their patents.  
 
The threat of legal action against physicians taught to prescribe economically is a major concern 
among health authorities already struggling to fund increased volumes and new high-priced 
medicines within available budgets (64). It also raises issues about off-label prescribing generally and 
pharmacists checking the use of medication with every patient (36). Moreover, it would seem that this 
is the first time that an originator company has threatened court cases against physicians in an 
extended patent use situation. Previous examples can be found in some countries, such as Lithuania 
(Table 2); however, no co-ordinated approach has been taken across countries. These concerns are 
exacerbated if such activities make European markets unattractive for generic companies, thereby 
reducing potential savings once a product loses its patent. It is also unhelpful to make physicians 
remember to prescribe different versions of the same molecule for different indications. This could, 
however, potentially be addressed through increasing use of electronic prescribing support systems. 
Actions of this nature also impede constructive working relationships between pharmaceutical 
companies and health service personnel (26). 
 
As seen in Tables 1±3, and Appendices 1 and 2, very different approaches have been taken across 
countries to the availability of generic pregabalin. In addition to historic approaches taken in Germany, 
countries such as Estonia, Republic of Srpska, Bosnia and Herzegovina, and Serbia (Table 3) are 
good examples of approaches taken to enhance the prescribing of pregabalin across all indications. 
The situation in Austria, Poland, and Slovenia will be closely monitored (Tables 2 and 3) to see if they 
could also provide examples of potential ways forward to enhance the prescribing of pregabalin 
across all indications.  
 
Lithuania, Norway and Sweden will also be closely monitored to see whether the originator company 
will be successful in limiting the prescribing of pregabalin in practice to epilepsy and GAD, with Lyrica 
prescribed and dispensed for neuropathic pain (Tables 2 and Appendix 2). Whether these countries 
will follow the examples of Estonia, Germany (historic), Republic of Srpska, Bosnia and Herzegovina, 
and Serbia (Table 3) once pregabalin is available and reimbursed remains to be seen. The outcome 
of potential marketing authorization and reimbursement of additional pregabalins in the Czech 
Republic, in addition to 3IL]HU¶VRZQJHQHULFSUHJDEDOLQ, will also be monitored given current 
uncertainties (Table 3). 
 
It is interesting to note the different approaches taken by the originator company to the KVs in 
Germany initially compared with regional health authorities in England and Health Boards in Scotland 
(Table 3). This acknowledges adherence to current stipulations of Social Code Book V serving as an 
example to other countries worried about such developments in the future, although this is now being 
challenged. 
 
The introduction of reference priced systems with reimbursement typically just covering the costs of 
the lowest priced molecule is another way forward, given the extent of internal reference pricing  
across Europe once multiple sources of a product become available (1). This works best if originator 
companies drop their prices to compete; alternatively, the situation is pre-empted as seen for instance 
in Spain (Table 3). Alternatively, the price of the originator (brand name) is reduced over time despite 
the protestations of the originator manufacturer, as seen in South Korea (Table 3). Difficulties could, 
potentially occur if reimbursement or substitution for one indication is not recommended, which could 
occur in Sweden for treatments for epilepsy (Table 2). This has not currently been a problem in South 
Korea with multiple pregabalin packs available from different manufacturers (Table 3). This situation 
could potentially reduce the attractiveness of the market to generic companies if originator (brand 
name) manufacturers are happy to drop their prices to those of generics to compete in the knowledge 
that patients may prefer to stay with the originator if co-payments are the same in the absence of any 
substitution in pharmacies. This is, however, being resisted by the originator company in South Korea 
(Table 3) 
 
The developments surrounding Lyrica and generic pregabalin, including potential health authority 
activities to enhance the prescribing of generic pregabalin, will be closely monitored over the coming 
months. This will be combined with research on the resultant effect of prescribing and dispensing of  
pregabalin or Lyrica in practice. The objective will be to provide further guidance to health authorities 
with their increasing need to maximize savings from generics or biosimilars once they become 
available for at least one indication. This is essential to maintain the ideals of comprehensive and 
equitable healthcare especially in Europe. 
 
Conclusion 
 
We have documented different approaches to the availability of generic pregabalin, with countries 
such as Germany historically having measures in place to enhance the prescribing of generics once 
at least one indication is off patent. This contrasts with countries such as the UK where generic 
pregabalin can only be prescribed for some but not all indications. This appreciably reduces potential 
savings from the availability of generics, which is an increasing concern given ever growing pressures 
on available resources.   
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